Sebastian Bauer, MD (he/him/his)

Attending, Director Sarcoma Center
Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Germany

Poster(s):

• (P 25) PREDICTING IMATINIB RESPONSES USING IN VITRO MODELS OF PDGFRA-MUTANT GASTROINTESTINAL STROMAL TUMOR

• (P 26) PHASE 1 STUDY OF IDRX-42 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS RESISTANT TO PRIOR SYSTEMIC THERAPY: EARLY RESULTS

• (P 47) PATIENT SURVIVAL IN METASTATIC GIST WITH IMATINIB-SENSITIVE MUTATIONS: REAL WORLD DATA FROM GERMAN REFERRAL CENTER (2008-2021)

• (P 49) EFFICACY OF RIPRETINIB IN A MULTICENTER EXPANDED ACCESS PROGRAM IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS HARBOURING NON-KIT EXON 11 MUTATIONS.

• (P 220) [68GA]GA-FAPI PET/CT AS NOVEL DIAGNOSTIC TOOL IN SARCOMA

• (P 234) GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA

• (P 248) FIBROBLAST ACTIVATION PROTEIN ALPHA -DIRECTED IMAGING AND THERAPY OF SOLITARY FIBROUS TUMOR

• (P 275) GIST-BSF1: A NOVEL SCF-DEPENDENT, WILD-TYPE KIT CELL LINE PLATFORM THAT ALLOWS RAPID GENERATION OF ISOGENIC SUBLINES WITH BOTH IMATINIB-SENSITIVE AND IMATINIB-RESISTANT GENOTYPES

• (P 276) REVISITING IN- AND OFF LABEL DRUGS FREQUENTLY USED IN METASTATIC GIST USING A BROAD IN VITRO PROFILING PANEL OF PRIMARY AND SECONDARY KIT AND PDGFRA-MUTANT GIST CELLS – CLINICAL IMPLICATIONS

• (P 294) DNA-DAMAGE REPAIR DYSREGULATION AND CHEMOTHERAPY RESPONSE IN SARCOMA MODELS